Exubera will be the first inhaled insulin to hit the Canadian market

Exubera will be the first inhaled insulin to hit the Canadian market later this month.

It's an alternative to short-acting or regular insulin.

Exubera will be used in combination with a longer-acting insulin for type 1 diabetes. For type 2 diabetes, it will be used alone...or with oral hypoglycemics...or a longer-acting insulin.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote